Worse PFS Seen with Nivolumab-Rucaparib in Ovarian CancerWorse PFS Seen with Nivolumab-Rucaparib in Ovarian Cancer
The addition of nivolumab to rucaparib did not lead to better progression-free survival than rucaparib monotherapy in patients with newly diagnosed, advanced, high-grade ovarian cancer (AHGOC), a new study has [...]